Access to Medicines
Dec 9, 2009 Wikileaks documents related to the WHO EWG
Submitted by Malini Aisola on 21. January 2010 - 9:30On December 9, 2009, Wikileaks posted five sensitive documents related to the WHO Expert Working Group (EWG) on R&D Financing:
a non-public draft report of the WHO EWG a non-public Comparative Analysis done by the EWG the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Overview of the EWG Comparative Analysis an IFPMA summary slide on the EWG Draft Report
Open Letter to the WHO EB from Cecilia López Montaño, EWG member
Submitted by Malini Aisola on 17. January 2010 - 20:54The following is a letter sent by Cecilia López Montaño, a member of the WHO Expert Working Group on R&D Financing to the WHO Executive Board:
Dear members of the Executive Board:
I am Cecilia López Montaño, senator of the Colombian Congress and member of the Expert Working Group on Research and Development Financing of the World Health Organization, in representation of the point of view of developing countries, I assume.
Can the U.S. realistically honor commitments to fund treatment for AIDS in developing countries without generic products?
Submitted by James Love on 12. January 2010 - 22:34KEI Statement on UNITAID Decision to Approve Creation of a Patent Pool for AIDS medicines
Submitted by James Love on 15. December 2009 - 1:22On Monday, December 14, the UNITAID board passed a resolution to establish a Patent Pool for AIDS medicines. The decision caped a dramatic debate on the proposal, which had been before UNITAID since 2006, and had been discussed in other fora since 2002. The following is a statement by KEI on the UNITAID decision, followed by background on the UNITAID patent pool proposal, including a copy of the UNITAID press release.
Statement of James Love, Director of KEI, on the UNITAID Patent Pool:
Speech of Mike Foster, UK Minister for International Development at launch of Industry Government Forum on Access to Medicines
Submitted by thiru on 21. October 2009 - 4:32On October 12, 2009, the "Industry Government Forum on Access to Medicines" (IGFAM) was launched. The UK Minister for International Development, MP Mike Foster made a a speech to launch this initiative which is reproduced below.
Presentations were also made by Pfizer (Ponni Subbiah), GSK (Abbas Hussain), Rajiv Venkayya (Gates Foundation), Prashant Yadav (Massachusetts Institute of Technology) and Suerie Moon (Research Fellow and Doctoral Candidate, Kennedy School of Government, Harvard University).
The Right to Development Criteria, applied to TDR and the Global Fund
Submitted by James Love on 18. September 2009 - 5:50For several years, the UN Human Rights Council (HRC) has been working on mechanisms to implement a 1986 UN Resolution on the "Right to Development." To this end, the HRC has created a Working Group on the Right to Development, and a High Level Task Force On The Implementation Of The Right To Development.
Letter to WHO on EML
Secretary of the Expert Committee on the
Selection and Use of Essential Medicines (2007)
Department of Medicines Policy and Standards (PSM)
Health Technology & Pharmaceuticals
World Health Organization
CH-1211 Geneva 27
Switzerland
Via e-mail: emisecretariat@who.int
RE: Request for changes in the WHO Model EML
KEI Comments to EWG 2nd Web-based Public Hearing: Defending the Status Quo, or Roadmap for Change?
Submitted by James Love on 6. September 2009 - 6:43On Saturday, KEI filed comments with the WHO EWG's 2nd web based hearing. Our comments focused on the criteria for new proposals.
WHO IGWG Negotiation
Submitted by Judit Rius on 1. September 2009 - 15:28Bring content from: http://www.keionline.org/content/view/3/1/
WHO Expert Working Group on R&D Financing (EWG)
Submitted by Staff on 1. September 2009 - 13:44WHO website on the EWG
NEWS: The EWG secretariat has released a draft evaluation framework, evaluation criteria and the inventory of financing proposals. The EWG is accepting public comments through the Second Web-based Public Hearing. Deadline: September 5 2009. KEI has offered critical comments on the criteria.